Brief: Kineta Unveils New Vista Biomarker Data And Kva12123 Phase 1/2 Clinical Trial Update At Aacr Annual Meeting 2023
17/04/2023 12:02
April 17 (Reuters) - Kineta Inc KA.O :
* KINETA UNVEILS NEW VISTA BIOMARKER DATA AND KVA12123 PHASE
1/2
CLINICAL TRIAL UPDATE AT AACR ANNUAL MEETING 2023
Source text for Eikon: ID:nGNXGyGWS
Further company coverage: KA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study